Tag - Arch

Developments

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced that Royal Columbian Hospital (RCH) has dosed its first patient in the ongoing Phase 2 trial evaluating LSALT peptide as a new drug to prevent acute kidney...

May 22, 2026

Uncategorized

Arch scientists publish new data linking cytokine IL-32 to DKD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) announced a scientific team, led by principal scientist Dr. Justin Chun at the University of Calgary, report in the peer-reviewed journal Inflammation Research that...

February 9, 2026

Executive Moves

Arch names Dr. Patrick Vink as chairman of BOD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced the appointment of Dr. Patrick Vink as chairman of the company’s board of directors (BOD), effective January 15, 2026. Dr. Vink, MD, MBA, has been an advisor to...

January 16, 2026

Developments

Arch announces non-brokered private placement

Arch BioPartners (TXSV:ARCH; QTCQB:ACHFF) has arranged a non-brokered private placement of 225,806 common shares at $1.55 per share, generating proceeds of CAD $350,000. According to Arch, the offering, set to close...

March 5, 2025

Tag - Arch

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Arch scientists publish new data linking cytokine IL-32 to DKD

Arch names Dr. Patrick Vink as chairman of BOD

Arch announces non-brokered private placement

Subscribe